Boston Scientific Corporation (BSX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 10 | 12 | 13 | 14 | 17 | 20 | 21 | 21 |
| Operating profit | $bn | 4 | 5 | ||||||
| Net profit | $bn | -0 | 1 | 1 | 2 | 2 | 3 | 4 | 5 |
| EPS reported | $ | 1.94 | 2.46 | ||||||
| Operating cashflow per share | $ | 3.06 | 3.07 | ||||||
| Capex per share | $ | 0.59 | 0.61 | ||||||
| FCF per share | $ | 2.47 | 2.45 | ||||||
| Free cash flow | $bn | 4 | 4 | ||||||
| Net debt | $bn | 10 | 12 | ||||||
| Book value equity | $bn | 24 | 25 | ||||||
| Book value per share | $ | 16.21 | 16.79 | ||||||
| Number of shares | m | 1,494.5 | 1,484.9 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 49.15 | 17.85 | ||||||
| P/B LTM | x | 5.82 | 5.66 | ||||||
| P/S LTM | x | 7.03 | 6.72 | ||||||
| P/FCF LTM | x | 38.59 | 38.94 | ||||||
| EV/EBITDA LTM | x | 29.70 | 26.67 | ||||||
| EV/Sales LTM | x | 7.55 | 3.96 | ||||||
| Earnings Yield LTM | % | +2.03% | +5.60% | ||||||
| FCF Yield | % | +2.59% | +2.57% | ||||||
| Quality | |||||||||
| ROE | % | +11.91% | +14.90% | ||||||
| ROIC | % | +8.78% | +10.57% | ||||||
| Operating margin | % | +19.78% | +21.46% | ||||||
| Gross margin | % | +69.01% | +71.16% | ||||||
| FCF/Sales | % | +18.22% | +17.27% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +55.20% | +96.80% | ||||||
| Sales Growth YoY | % | +19.87% | +25.37% | ||||||
| Net Income Growth YoY | % | +55.66% | +97.79% | ||||||
| FCF Growth | % | +38.30% | +37.05% | ||||||
| Operating Profit Growth | % | +50.70% | +71.01% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.29 | 0.29 | ||||||
| Net Debt/EBITDA | x | 2.03 | 2.13 | ||||||
| EBIT/Net interest | x | 11.38 | 12.41 | ||||||
| Net debt/market cap | % | +8.39% | +17.59% | ||||||
| Net debt/Equity | x | 0.40 | 0.48 | ||||||
| Gross debt/equity | x | 0.51 | 0.51 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Boston Scientific Corporation (BSX)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free